CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer

被引：0
|
作者：
Himelstein, Andrew Louis
Qin, Rui
Novotny, Paul J.
Seisler, Drew K.
Khatcheressian, James L.
Roberts, John D.
Grubbs, Stephen S.
O'Connor, Tracey
Weckstein, Douglas
Loprinzi, Charles L.
Shapiro, Charles L.
机构：
[1] Helen F Graham Canc Ctr & Res Inst, Newark, DE USA
[2] Mayo Clin, Alliance Stat & Data Ctr, Rochester, MN USA
[3] Virginia Canc Inst, Richmond, VA USA
[4] Yale Univ, New Haven, CT USA
[5] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[6] New Hampshire Onc Hem PA, Hooksett, NH USA
[7] Mayo Clin, Rochester, MN USA
[8] Mt Sinai Sch Med, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9501
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Topical Hyaluronic Acid vs. Standard of Care for the Prevention of Radiation Dermatitis After Adjuvant Radiotherapy for Breast Cancer: Single-Blind Randomized Phase III Clinical Trial
    Pinnix, Chelsea
    Perkins, George H.
    Strom, Eric A.
    Tereffe, Welela
    Woodward, Wendy
    Oh, Julia L.
    Arriaga, Lisa
    Munsell, Mark F.
    Kelly, Patrick
    Hoffman, Karen E.
    Smith, Benjamin D.
    Buchholz, Thomas A.
    Yu, T. Kuan
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 83 (04): : 1089 - 1094
  • [22] Regorafenib Dose Optimization Study (ReDOS): Randomized Phase II Trial to Evaluate Dosing Strategies for Regorafenib in Refractory Metastatic Colorectal Cancer-An ACCRU Network Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 9 - 10
  • [23] ADHERENCE WITH TELAPREVIR BID vs. q8h DOSING IN TREATMENT-NAIVE HCV-INFECTED PATIENTS: RESULTS FROM THE PHASE III OPTIMIZE STUDY
    Sievert, W.
    Buti, M.
    Agarwal, K.
    Horsmans, Y.
    Zeuzem, S.
    Janczewska, E.
    Nyberg, L.
    Brown, R. S., Jr.
    Hezode, C.
    Rizzetto, M.
    Parana, R.
    De Meyer, S.
    De Masi, R.
    Luo, D.
    Witek, J.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S373 - S373
  • [24] Phase III study of zoledronic acid versus pamidronate in patients with metastatic bone lesions due to breast cancer or multiple myeloma: Preliminary results.
    Major, P
    Body, JJ
    Carranza, H
    Vorlicek, J
    Jantunen, E
    Chiara, S
    Torroba, JD
    Baltai, E
    Meyer, A
    ANNALS OF ONCOLOGY, 2000, 11 : 153 - 153
  • [25] Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC):: A prospective, randomized multicentre phase III study of the AGO breast cancer study group.
    Lueck, H.
    Minckwitz, G. V.
    Du Bois, A.
    Schrader, I.
    Huober, J.
    Heilmann, V.
    Beckmann, M.
    Stähle, A.
    Jackisch, C.
    Marth, C.
    Richter, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 7S - 7S
  • [26] A Randomized Phase II Study of Sunitinib vs. Standard of Care for Patients with Previously Treated Advanced Triple-Negative Breast Cancer
    Curigliano, G.
    Pivot, X.
    Cortes, J.
    Elias, A.
    Cesari, R.
    Collier, M.
    Huang, X.
    Cataruozolo, P. E.
    Kern, K. A.
    Goldhirsch, A.
    CANCER RESEARCH, 2010, 70
  • [27] Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)
    Morris, Michael J.
    Heller, Glenn
    Hillman, David W.
    Bobek, Olivia
    Ryan, Charles
    Antonarakis, Emmanuel S.
    Bryce, Alan H.
    Hahn, Olwen
    Beltran, Himisha
    Armstrong, Andrew J.
    Schwartz, Lawrence
    Lewis, Lionel D.
    Beumer, Jan H.
    Langevin, Brooke
    McGary, Eric C.
    Mehan, Paul T.
    Goldkorn, Amir
    Roth, Bruce J.
    Xiao, Han
    Watt, Colleen
    Taplin, Mary-Ellen
    Halabi, Susan
    Small, Eric J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (18) : 3352 - +
  • [28] Zoledronic acid with either standard or reduced dose palliative radiotherapy in the management of the breast cancer patients with bone metastases:: A phase IV randomized study.
    Atahan, L.
    Yildiz, F.
    Cengiz, M.
    Kaplan, B.
    Ozkan, M.
    Haydaroglu, A.
    Sengoz, M.
    Korcums, A. F.
    Akmansu, M.
    Engin, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S524 - S525
  • [29] Lefitolimod vs standard of care (SOC) for patients with metastatic colorectal cancer (mCRC) responding to first-line standard treatment: Results from the randomized phase III IMPALA trial
    Cunningham, D.
    Salazar, R.
    Sobrero, A.
    Ducreux, M. P.
    Van Cutsem, E.
    Scheithauer, W.
    Tournigand, C.
    Molnar, V.
    Starke, M.
    Baumann, M.
    Wiegert, E.
    Schmidt, M.
    Arnold, D.
    ANNALS OF ONCOLOGY, 2019, 30
  • [30] Zoledronic acid with either standard or reduced dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: A phase IV randomized study.
    Atahan, I. L.
    Yildiz, F.
    Cengiz, M.
    Kaplan, B.
    Ozkan, M.
    Haydaroglu, A.
    Sengoz, M.
    Korcum, A. F.
    Akmansu, M.
    Engin, K.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S150 - S151
12345